Ask a research question about Gout. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).
Do not include personal health information in your question. Questions and results are cached in your browser's local storage.
name: Gout
creation_date: '2025-12-18T17:01:35Z'
updated_date: '2026-05-12T00:25:12Z'
category: Complex
parents:
- Metabolic Disease
- Musculoskeletal Disease
disease_term:
preferred_term: gout
term:
id: MONDO:0005393
label: gout
pathophysiology:
- name: Hyperuricemia
description: >
Elevated serum uric acid from increased purine metabolism or decreased
renal excretion leads to supersaturation and crystal formation.
Urate is the end product of purine catabolism in humans.
genes:
- preferred_term: SLC2A9
term:
id: hgnc:13446
label: SLC2A9
- preferred_term: ABCG2
term:
id: hgnc:74
label: ABCG2
- preferred_term: SLC22A12
term:
id: hgnc:17989
label: SLC22A12
biological_processes:
- preferred_term: Purine Metabolism
term:
id: GO:0006144
label: purine nucleobase metabolic process
evidence:
- reference: PMID:38972919
reference_title: "Unraveling the pathological biomineralization of monosodium urate crystals in gout patients."
supports: SUPPORT
snippet: "Crystallization of monosodium urate monohydrate (MSU) leads to painful
gouty arthritis."
explanation: Establishes that hyperuricemia-driven MSU crystallization is
the fundamental pathological process in gout.
- name: Crystal Deposition
description: >
Monosodium urate (MSU) crystals deposit in joints and soft tissues
when serum urate exceeds saturation point (~6.8 mg/dL). Crystals
trigger inflammatory response.
evidence:
- reference: PMID:38972919
reference_title: "Unraveling the pathological biomineralization of monosodium urate crystals in gout patients."
supports: SUPPORT
snippet: "inflammatory MSU crystals form after a non-inflammatory amorphous precursor
(AMSU) that nucleates heterogeneously on collagen fibrils from damaged articular
cartilage of gout patients"
explanation: Describes the non-classical crystallization pathway where MSU
forms via an amorphous precursor on damaged cartilage collagen, explaining
the anatomical specificity of crystal deposition.
- reference: PMID:38972919
reference_title: "Unraveling the pathological biomineralization of monosodium urate crystals in gout patients."
supports: SUPPORT
snippet: "This non-classical crystallization route imprints a nanogranular structure
to biogenic acicular MSU crystals, which have smaller unit cell volume, lower
microstrain, and higher crystallinity than synthetic MSU."
explanation: Characterizes the unique structural properties of pathological
MSU crystals that form in vivo at low supersaturation over extended time
periods.
- name: Inflammasome Activation
description: >
MSU crystals are phagocytosed by macrophages, activating NLRP3
inflammasome and triggering IL-1beta release, driving acute
inflammatory flare.
cell_types:
- preferred_term: Macrophage
term:
id: CL:0000235
label: macrophage
cellular_components:
- preferred_term: NLRP3 inflammasome complex
term:
id: GO:0072559
label: NLRP3 inflammasome complex
evidence:
- reference: PMID:39386881
reference_title: "Mechanism of macrophages in gout: Recent progress and perspective."
supports: SUPPORT
snippet: "Gout represents an autoinflammatory disorder instigated by monosodium
urate crystals. Its primary manifestation involves the recruitment of diverse
immune cell populations, including neutrophils and macrophages. Macrophages
assume a pivotal role in the initiation of acute gouty inflammation and subsequent
inflammatory cascades."
explanation: Establishes the central role of macrophages in initiating and
propagating the acute inflammatory response to MSU crystals in gout.
- reference: PMID:39386881
reference_title: "Mechanism of macrophages in gout: Recent progress and perspective."
supports: SUPPORT
snippet: "Macrophages, characterized by different subtypes, exhibit distinct functionalities
that either contribute to the progression or regression of gout."
explanation: Demonstrates that macrophages have complex, context-dependent
roles in both promoting and resolving gouty inflammation depending on
their polarization state.
- reference: PMID:39426967
reference_title: "Effective xanthine oxidase inhibitor urate lowering therapy in gout is linked to an emergent serum protein interactome of complement and inflammation modulators."
supports: SUPPORT
snippet: "At 48 weeks ULT, serum urate normalized in all gout patients, and flares
declined in association with significantly altered proteins (p < 0.05) in clustering
and proteome networks in sera and peripheral blood mononuclear cells."
explanation: Shows that effective urate-lowering therapy modulates immune
cell proteomes, including those relevant to inflammasome activation,
correlating with reduced flare burden.
- name: Neutrophil Recruitment
description: >
IL-1beta and other cytokines recruit neutrophils to the joint,
amplifying inflammation and causing the intense pain and swelling
of acute gout attacks.
cell_types:
- preferred_term: Neutrophil
term:
id: CL:0000775
label: neutrophil
evidence:
- reference: PMID:39386881
reference_title: "Mechanism of macrophages in gout: Recent progress and perspective."
supports: SUPPORT
snippet: "Its primary manifestation involves the recruitment of diverse immune
cell populations, including neutrophils and macrophages."
explanation: Confirms that neutrophil recruitment is a primary feature of
the acute gouty inflammatory response.
- reference: PMID:39426967
reference_title: "Effective xanthine oxidase inhibitor urate lowering therapy in gout is linked to an emergent serum protein interactome of complement and inflammation modulators."
supports: SUPPORT
snippet: "In both cohorts, a treatment-emergent serum interactome included key
gouty inflammation mediators (C5, IL-1B, CXCL8, IL6)."
explanation: Identifies IL-1B and CXCL8 as key mediators in the serum
interactome associated with gouty inflammation, supporting their role in
neutrophil recruitment and activation.
- name: Complement Activation
description: >
MSU crystals activate the complement system, particularly C5, contributing
to neutrophil recruitment and amplifying the inflammatory response.
Effective urate-lowering therapy modulates complement and inflammatory
protein networks.
evidence:
- reference: PMID:39426967
reference_title: "Effective xanthine oxidase inhibitor urate lowering therapy in gout is linked to an emergent serum protein interactome of complement and inflammation modulators."
supports: SUPPORT
snippet: "Sera demonstrated altered complement activation and regulatory gene
ontology biologic processes."
explanation: Demonstrates that complement activation pathways are altered in
gout and modulated by effective urate-lowering therapy.
- reference: PMID:39426967
reference_title: "Effective xanthine oxidase inhibitor urate lowering therapy in gout is linked to an emergent serum protein interactome of complement and inflammation modulators."
supports: SUPPORT
snippet: "Reduced gout flares are linked with a XOI treatment-emergent serum protein
interactome that includes inflammation regulators, associated with altered complement
activation and regulatory biologic processes."
explanation: Shows that reduction in gout flares correlates with changes in
complement activation pathways, establishing complement as a key
therapeutic target and biomarker.
- reference: PMID:39426967
reference_title: "Effective xanthine oxidase inhibitor urate lowering therapy in gout is linked to an emergent serum protein interactome of complement and inflammation modulators."
supports: SUPPORT
snippet: "Last, febuxostat treatment decreased complement activation biologic
process proteins in cultured BMDMs."
explanation: Provides mechanistic evidence that xanthine oxidase inhibitors
directly modulate complement activation in macrophages beyond their
urate-lowering effects.
- name: Neutrophil Extracellular Trap Formation
description: >
Neutrophils form extracellular traps (NETs) in response to MSU crystals.
NETs initially amplify inflammation but aggregated NETs (aggNETs) promote
resolution by encapsulating crystals, degrading cytokines, and blocking
further neutrophil recruitment. NETs also contribute to tophi formation.
cell_types:
- preferred_term: Neutrophil
term:
id: CL:0000775
label: neutrophil
evidence:
- reference: PMID:38910565
reference_title: "Mechanism of neutrophil extracellular traps in the pathogenesis of gout."
supports: SUPPORT
snippet: "Neutrophil extracellular traps (NETs) are formed by neutrophils in response
to pathogen attack. During gout, NETs induced by MSU crystals exacerbate inflammation,
and aggregated NETs (aggNETs) promote the resolution of gout-associated inflammation
by encapsulating MSU crystals, degrading cytokines and chemokines, and blocking
the recruitment and activation of neutrophils."
explanation: Describes the dual role of NETs in gout - initially amplifying
inflammation but then promoting resolution through aggregation and
sequestration mechanisms.
- reference: PMID:38910565
reference_title: "Mechanism of neutrophil extracellular traps in the pathogenesis of gout."
supports: SUPPORT
snippet: "With disease progression, NETs participate in the formation of tophi."
explanation: Establishes the role of NETs in chronic gout pathology,
specifically in the formation of tophi (urate crystal deposits).
- reference: PMID:38910565
reference_title: "Mechanism of neutrophil extracellular traps in the pathogenesis of gout."
supports: SUPPORT
snippet: "Therefore, aggNETs are a possible mechanism of spontaneous gout regression."
explanation: Identifies aggregated NETs as a key mechanism underlying the
self-limited nature of acute gout flares and spontaneous resolution.
phenotypes:
- name: Acute Arthritis
category: Musculoskeletal
frequency: VERY_FREQUENT
diagnostic: true
notes: Classically affects first MTP joint (podagra)
phenotype_term:
preferred_term: Arthritis
term:
id: HP:0001369
label: Arthritis
evidence:
- reference: PMID:38972919
reference_title: "Unraveling the pathological biomineralization of monosodium urate crystals in gout patients."
supports: SUPPORT
snippet: "Crystallization of monosodium urate monohydrate (MSU) leads to painful
gouty arthritis."
explanation: Directly links MSU crystal formation to the development of
painful acute arthritis in gout.
- reference: PMID:39386881
reference_title: "Mechanism of macrophages in gout: Recent progress and perspective."
supports: SUPPORT
snippet: "Macrophages assume a pivotal role in the initiation of acute gouty inflammation
and subsequent inflammatory cascades."
explanation: Explains the cellular mechanism underlying acute arthritis
through macrophage-mediated inflammatory cascade initiation.
- name: Joint Swelling
category: Musculoskeletal
frequency: VERY_FREQUENT
phenotype_term:
preferred_term: Joint Swelling
term:
id: HP:0001386
label: Joint swelling
- name: Joint Pain
category: Musculoskeletal
frequency: VERY_FREQUENT
phenotype_term:
preferred_term: Arthralgia
term:
id: HP:0002829
label: Arthralgia
- name: Nephrolithiasis
category: Renal
frequency: OCCASIONAL
notes: Uric acid stones
phenotype_term:
preferred_term: Kidney Stones
term:
id: HP:0000787
label: Nephrolithiasis
biochemical:
- name: Serum Uric Acid
presence: Elevated
context: Usually >6.8 mg/dL, may be normal during acute attack
readouts:
- target: Hyperuricemia
relationship: PHARMACODYNAMIC_MARKER_OF
direction: POSITIVE
endpoint_context: PHARMACODYNAMIC
regulatory_endpoint_refs:
- FDA-SE-adult-noncancer-029
interpretation: >-
Higher serum uric acid tracks the hyperuricemic biochemical state that
drives urate crystal supersaturation; reduction under xanthine oxidase
inhibitors, URAT1 inhibitors, or uricase reports pharmacodynamic
urate-lowering in gout.
evidence:
- reference: PMID:39426967
reference_title: "Effective xanthine oxidase inhibitor urate lowering therapy in gout is linked to an emergent serum protein interactome of complement and inflammation modulators."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
At 48 weeks ULT, serum urate normalized in all gout patients, and
flares declined in association with significantly altered proteins
explanation: >-
Supports serum urate normalization as a pharmacodynamic readout of
urate-lowering therapy in gout.
biomarker_term:
preferred_term: Serum Uric Acid Measurement
term:
id: NCIT:C61034
label: Serum Uric Acid Measurement
synonyms:
- Serum urate
- Uric acid
- name: CRP
presence: Elevated
context: Acute flare
- name: Synovial Fluid Crystals
presence: Present
context: Negatively birefringent MSU crystals diagnostic
genetic:
- name: SLC2A9
gene_term:
preferred_term: SLC2A9
term:
id: hgnc:13446
label: SLC2A9
association: Risk Factor
notes: Major urate transporter
- name: ABCG2
gene_term:
preferred_term: ABCG2
term:
id: hgnc:74
label: ABCG2
association: Risk Factor
notes: Urate efflux transporter
- name: SLC22A12
gene_term:
preferred_term: SLC22A12
term:
id: hgnc:17989
label: SLC22A12
association: Risk Factor
notes: URAT1 urate reabsorption
environmental:
- name: Red Meat and Organ Meat Intake
notes: Purine-rich mammalian meat raises urate burden
food_source:
preferred_term: mammalian meat food product
term:
id: FOODON:00001006
label: mammalian meat food product
- name: Shellfish Intake
notes: Purine-rich shellfish can precipitate hyperuricemia and flares
food_source:
preferred_term: shellfish food product
term:
id: FOODON:00001293
label: shellfish food product
- name: Beer Intake
notes: Beer impairs urate excretion and contributes purine load
food_source:
preferred_term: beer beverage
term:
id: FOODON:00001260
label: beer beverage
- name: Fructose-Sweetened Soft Drink Intake
notes: Fructose-containing soft drinks increase urate production
- name: Dehydration
notes: Concentrates urate
- name: Diuretics
notes: Reduce urate excretion
treatments:
- name: NSAIDs
description: First-line for acute flares (indomethacin, naproxen).
evidence:
- reference: PMID:32391934
supports: SUPPORT
snippet: "For management of gout flares, colchicine, nonsteroidal antiinflammatory
drugs, or glucocorticoids (oral, intraarticular, or intramuscular) were strongly
recommended."
explanation: The 2020 ACR guideline strongly recommends NSAIDs as first-line
treatment for acute gout flares.
- name: Colchicine
description: Effective for acute flares and prophylaxis.
evidence:
- reference: PMID:32391934
supports: SUPPORT
snippet: "For management of gout flares, colchicine, nonsteroidal antiinflammatory
drugs, or glucocorticoids (oral, intraarticular, or intramuscular) were strongly
recommended."
explanation: The 2020 ACR guideline strongly recommends colchicine as first-line
treatment for acute gout flares.
- name: Corticosteroids
description: Alternative for acute flares when NSAIDs contraindicated.
evidence:
- reference: PMID:32391934
supports: SUPPORT
snippet: "For management of gout flares, colchicine, nonsteroidal antiinflammatory
drugs, or glucocorticoids (oral, intraarticular, or intramuscular) were strongly
recommended."
explanation: The 2020 ACR guideline strongly recommends glucocorticoids as first-line
treatment for acute gout flares.
- name: Allopurinol
description: Xanthine oxidase inhibitor for urate-lowering therapy.
evidence:
- reference: PMID:39426967
reference_title: "Effective xanthine oxidase inhibitor urate lowering therapy in gout is linked to an emergent serum protein interactome of complement and inflammation modulators."
supports: SUPPORT
snippet: "Urate-lowering treatment (ULT) to target with xanthine oxidase inhibitors
(XOIs) paradoxically causes early increase in gouty arthritis flares."
explanation: Describes the paradoxical early flare phenomenon with XOI
treatment, an important clinical consideration.
- reference: PMID:39426967
reference_title: "Effective xanthine oxidase inhibitor urate lowering therapy in gout is linked to an emergent serum protein interactome of complement and inflammation modulators."
supports: SUPPORT
snippet: "At 48 weeks ULT, serum urate normalized in all gout patients, and flares
declined in association with significantly altered proteins (p < 0.05) in clustering
and proteome networks in sera and peripheral blood mononuclear cells."
explanation: Demonstrates that sustained XOI urate-lowering therapy
normalizes serum urate and reduces flares through modulation of immune
proteomes.
- name: Febuxostat
description: Alternative xanthine oxidase inhibitor.
evidence:
- reference: PMID:39426967
reference_title: "Effective xanthine oxidase inhibitor urate lowering therapy in gout is linked to an emergent serum protein interactome of complement and inflammation modulators."
supports: SUPPORT
snippet: "Last, febuxostat treatment decreased complement activation biologic
process proteins in cultured BMDMs."
explanation: Shows that febuxostat has anti-inflammatory effects beyond
urate lowering by modulating complement activation in macrophages.
- name: Probenecid
description: Uricosuric agent increasing renal urate excretion.
- name: Pegloticase
description: Recombinant uricase for refractory gout.
classifications:
harrisons_chapter:
- classification_value: musculoskeletal system disorder
- classification_value: inflammatory arthritis
datasets:
references:
- reference: DOI:10.1007/s11606-024-08793-9
title: 'Empagliflozin and Risk of Incident Gout: Analysis from the EMPagliflozin
Comparative Effectiveness and SafEty (EMPRISE) Cohort Study'
findings: []
- reference: DOI:10.1016/j.heliyon.2024.e38288
title: 'Mechanism of macrophages in gout: Recent progress and perspective'
findings: []
- reference: DOI:10.1038/s41598-024-74154-5
title: Effective xanthine oxidase inhibitor urate lowering therapy in gout is
linked to an emergent serum protein interactome of complement and
inflammation modulators
findings: []
- reference: DOI:10.1038/s42003-024-06534-6
title: Unraveling the pathological biomineralization of monosodium urate
crystals in gout patients
findings: []
- reference: DOI:10.1093/rheumatology/keae420
title: Association of rare and common genetic variants in <i>MOCOS</i> with
inadequate response to allopurinol
findings: []
- reference: DOI:10.1136/bmj-2024-080035
title: 'Comparative effectiveness of sodium-glucose cotransporter-2 inhibitors for
recurrent nephrolithiasis among patients with pre-existing nephrolithiasis or
gout: target trial emulation studies'
findings: []
- reference: DOI:10.3389/fendo.2023.1071630
title: Neutrophil autophagy induced by monosodium urate crystals facilitates
neutrophil extracellular traps formation and inflammation remission in gouty
arthritis
findings: []
- reference: DOI:10.3390/gucdd2020016
title: Regulation of Urate Homeostasis by Membrane Transporters
findings: []
- reference: DOI:10.3390/ph17111507
title: 'The Therapeutic Management of Chemical and Herbal Medications on Uric Acid
Levels and Gout: Modern and Traditional Wisdom'
findings: []
- reference: DOI:10.3390/pharmaceutics17010102
title: 'Current Status of Gout Arthritis: Current Approaches to Gout Arthritis Treatment:
Nanoparticles Delivery Systems Approach'
findings: []
- reference: DOI:10.55563/clinexprheumatol/ezzfbt
title: Mechanism of neutrophil extracellular traps in the pathogenesis of gout
findings: []
- reference: DOI:10.7326/m23-0724
title: Comparative Effectiveness of Sodium–Glucose Cotransporter-2 Inhibitors
for Recurrent Gout Flares and Gout-Primary Emergency Department Visits and
Hospitalizations
findings: []
Disease Pathophysiology Research Report
Target Disease - Disease Name: Gout - MONDO ID: - Category: Complex
Pathophysiology Description Gout is a sterile, crystal-driven inflammatory arthritis initiated by supersaturation of urate and deposition of monosodium urate (MSU) crystals within and around synovial joints. Innate immune sensing of MSU—particularly through the NLRP3 inflammasome in tissue macrophages—leads to caspase‑1 activation, maturation/release of IL‑1β and IL‑18, and downstream neutrophil recruitment, NET formation, and acute synovitis. Chronic, inadequately controlled crystal burden organizes into tophi that sustain granulomatous inflammation, osteoclast activation via RANKL, and bone erosion. Uric acid homeostasis is genetically and physiologically determined by hepatic xanthine oxidoreductase (XOR) production and renal/intestinal transporter-mediated excretion (notably SLC2A9/GLUT9 and ABCG2), explaining the strong heritable component and the predominance of under‑excretion in hyperuricemia. Recent 2023–2024 studies refine core mechanisms: (i) MSU biomineralizes in vivo via a non-classical route that begins as an amorphous precursor on damaged cartilage collagen; (ii) neutrophils form NETs that both amplify and, when aggregated, help resolve flares; (iii) macrophage inflammasome activation is coupled to gasdermin D–dependent pyroptosis and is modulated by complement, redox, and metabolic cues; and (iv) effective urate-lowering remodels a serum interactome enriched for complement and inflammatory proteins, aligning with the clinical fall in flare burden over time. (sanchez2024effectivexanthineoxidase pages 8-9, herdiana2025currentstatusof pages 2-4, tan2024mechanismofmacrophages pages 2-4, tan2024mechanismofmacrophages pages 11-12, sanchez2024effectivexanthineoxidase pages 9-10)
Core Pathophysiology 1) Primary mechanisms - Hyperuricemia and crystal deposition: Humans lack uricase; uric acid is the end-product of purine catabolism via XOR. Urate supersaturation fosters MSU crystal nucleation in cooler, damaged periarticular tissues. (lin2024thetherapeuticmanagement pages 5-6, lin2024thetherapeuticmanagement pages 2-5) - Innate immune sensing: MSU crystals are engulfed by synovial macrophages, providing priming (e.g., TLR–NF‑κB) and activation signals for NLRP3, with assembly of NLRP3–ASC–pro‑caspase‑1, caspase‑1 activation, and IL‑1β/IL‑18 maturation. (tan2024mechanismofmacrophages pages 2-4, tan2024mechanismofmacrophages pages 11-12) - Neutrophil influx and NETs: IL‑1β and chemokines recruit neutrophils, which generate NETs that initially perpetuate synovitis yet can aggregate (aggNETs) to sequester cytokines and crystals, contributing to spontaneous resolution. Autophagy in neutrophils promotes NET formation and flare remission in vivo. (herdiana2025currentstatusof pages 2-4, chen2024mechanismofneutrophil pages 8-8) - Complement engagement: MSU activates complement (C5 convertase assembly on crystal surfaces; MAC contributes to neutrophilic synovitis). Neutrophil microvesicles can dampen C5a priming of the inflammasome, aiding resolution. (sanchez2024effectivexanthineoxidase pages 9-10) - Pyroptosis: Inflammasome‑caspase‑1 activation triggers gasdermin D–mediated pore formation and pyroptotic cell death in macrophages (and, size‑dependently, in neutrophils), amplifying cytokine release. (tan2024mechanismofmacrophages pages 2-4, chen2024mechanismofneutrophil pages 8-8)
2) Dysregulated molecular pathways - NLRP3–caspase‑1–IL‑1β/IL‑18 axis: Central to acute flares; multiple regulators modulate threshold (cathepsin B, TRPV4 mechanosensing, complement C5a/C5aR2, purinergic receptors, mitochondrial ROS and glycolytic reprogramming). (tan2024mechanismofmacrophages pages 11-12) - XOR/ROS: XOR contributes ROS that support inflammasome activation; XO inhibitors exert anti‑inflammatory effects beyond urate lowering. (sanchez2024effectivexanthineoxidase pages 9-10) - Complement pathways: C5 activation, MAC deposition, and complement regulatory changes are linked to flare dynamics and to the proteomic remodeling observed with effective urate‑lowering therapy. (sanchez2024effectivexanthineoxidase pages 9-10, sanchez2024effectivexanthineoxidase pages 8-9)
3) Affected cellular processes - Phagocytosis of MSU and inflammasome assembly (macrophages). (tan2024mechanismofmacrophages pages 2-4) - NETosis and aggNET‑mediated cytokine degradation (neutrophils). (herdiana2025currentstatusof pages 2-4, chen2024mechanismofneutrophil pages 8-8) - Pyroptosis via gasdermin D (myeloid cells). (chen2024mechanismofneutrophil pages 8-8) - Autophagy–NET crosstalk in remission. (herdiana2025currentstatusof pages 2-4)
Key Molecular Players - Genes/Proteins (HGNC): SLC2A9/GLUT9; ABCG2; SLC22A12/URAT1; SLC22A11/OAT4; SLC17A1/NPT1; MOCOS; NLRP3; CASP1; IL1B; IL18; GSDMD. (lin2024thetherapeuticmanagement pages 2-5, sanchez2024effectivexanthineoxidase pages 9-10, tan2024mechanismofmacrophages pages 2-4, tan2024mechanismofmacrophages pages 11-12) - Chemical entities (CHEBI): uric acid/urate; monosodium urate; allopurinol; febuxostat; canakinumab; anakinra; colchicine; SGLT2 inhibitor class. (lin2024thetherapeuticmanagement pages 5-6, sanchez2024effectivexanthineoxidase pages 9-10) - Cell types (CL): synovial/tissue macrophages; neutrophils; mast cells (early mediator release). (tan2024mechanismofmacrophages pages 2-4, herdiana2025currentstatusof pages 2-4, lin2024thetherapeuticmanagement pages 2-5) - Anatomical locations (UBERON): synovium; cartilage; subchondral bone; kidney; intestine. (sanchez2024effectivexanthineoxidase pages 8-9, lin2024thetherapeuticmanagement pages 2-5)
Biological Processes (GO) for annotation - Inflammasome activation; interleukin‑1β maturation; complement activation; NET formation (NETosis); pyroptosis; autophagy; biomineralization of MSU; urate transport and transmembrane transport. (tan2024mechanismofmacrophages pages 2-4, herdiana2025currentstatusof pages 2-4, sanchez2024effectivexanthineoxidase pages 9-10, sanchez2024effectivexanthineoxidase pages 8-9, lin2024thetherapeuticmanagement pages 2-5)
Cellular Components - Cytosol/ASC specks (inflammasome foci), mitochondria (ROS), endolysosomal compartments (cathepsin B), plasma membrane (GSDMD pores), extracellular space (MSU crystals, NETs), complement components in serum/plasma. (tan2024mechanismofmacrophages pages 2-4, tan2024mechanismofmacrophages pages 11-12, sanchez2024effectivexanthineoxidase pages 9-10)
Disease Progression - Sequence of events: 1) Hyperuricemia due to increased production (XOR activity, purine/fructose load) or decreased excretion (renal/intestinal transporter function) (lin2024thetherapeuticmanagement pages 5-6, lin2024thetherapeuticmanagement pages 2-5). 2) Tissue microenvironmental triggers (cooler temperature, pH, cartilage damage) facilitate MSU nucleation and growth. Recent human biomineralization work shows “inflammatory MSU crystals form after a non‑inflammatory amorphous precursor (AMSU) that nucleates heterogeneously on collagen fibrils from damaged articular cartilage” and grow slowly at low supersaturation (Communications Biology, 2024; https://doi.org/10.1038/s42003-024-06534-6; published July 2024). (sanchez2024effectivexanthineoxidase pages 8-9) 3) Inflammasome‑IL‑1–neutrophil axis produces acute gouty synovitis with potential amplification by complement. (tan2024mechanismofmacrophages pages 2-4, sanchez2024effectivexanthineoxidase pages 9-10) 4) Resolution via aggNET‑driven cytokine degradation and regulatory microvesicles; intercritical period with persistent crystal burden. (herdiana2025currentstatusof pages 2-4, sanchez2024effectivexanthineoxidase pages 9-10) 5) Chronic tophaceous gout: tophi as granuloma‑like structures encasing MSU with ongoing macrophage/neutrophil activity; RANKL expression promotes osteoclastogenesis and bone erosion. (herdiana2025currentstatusof pages 2-4)
Phenotypic Manifestations (selected HP terms) - Acute monoarthritis with severe pain, swelling, erythema (HP:0001370 Arthralgia; HP:0002829 Joint swelling) driven by IL‑1β–neutrophil axis. (tan2024mechanismofmacrophages pages 2-4) - Tophi (HP:0100730 Subcutaneous nodule) and chronic tophaceous gout with bone erosions (HP:0002757 Osteolysis) mediated by RANKL‑driven osteoclast activity. (herdiana2025currentstatusof pages 2-4) - Nephrolithiasis risk and urate nephropathy due to hyperuricosuria/hyperuricemia (HP:0000787 Nephrolithiasis). (lin2024thetherapeuticmanagement pages 2-5)
Evidence Highlights and Quotations (2023–2024 focus) - MSU biomineralization in human tissue: “inflammatory MSU crystals form after a non‑inflammatory amorphous precursor (AMSU) that nucleates heterogeneously on collagen fibrils from damaged articular cartilage of gout patients” (Communications Biology; July 2024; https://doi.org/10.1038/s42003-024-06534-6). (sanchez2024effectivexanthineoxidase pages 8-9) - Macrophage inflammasome regulation: the NLRP3 inflammasome in macrophages is activated by MSU with priming via TLR/NF‑κB, and modulated by cathepsin B, complement C5a signaling, ionic flux/mechanosensing, and metabolic reprogramming (Heliyon; Oct 2024; https://doi.org/10.1016/j.heliyon.2024.e38288). (tan2024mechanismofmacrophages pages 11-12) - NETs in pathogenesis and resolution: MSU‑induced NETs/aggNETs both exacerbate and resolve inflammation; neutrophil autophagy promotes NETs and “alleviate[s] the inflammatory response in gouty arthritis” in mouse models (Frontiers in Endocrinology; Sept 2023; https://doi.org/10.3389/fendo.2023.1071630). (herdiana2025currentstatusof pages 2-4, chen2024mechanismofneutrophil pages 8-8) - Complement and proteomic remodeling with ULT: sustained XO inhibitor ULT associates with an emergent serum interactome of complement and inflammatory modulators; MSU‑induced synovitis involves C5 activation and MAC (Scientific Reports; Oct 2024; https://doi.org/10.1038/s41598-024-74154-5). (sanchez2024effectivexanthineoxidase pages 9-10, sanchez2024effectivexanthineoxidase pages 8-9) - Urate transporters and genetics: updated evidence confirms SLC2A9/GLUT9 and ABCG2 as major determinants of urate handling; ABCG2 mediates intestinal urate export (Gout, Urate, and Crystal Deposition Disease; June 2024; https://doi.org/10.3390/gucdd2020016). (lin2024thetherapeuticmanagement pages 2-5) - Pharmacogenetics of allopurinol response: “common and rare genetic variation in MOCOS associat[es] with allopurinol response” in whole‑genome sequenced gout participants of LASSO (Rheumatology (Oxford); Aug 2024; https://doi.org/10.1093/rheumatology/keae420). (sanchez2024effectivexanthineoxidase pages 9-10)
Current Applications and Real‑World Implementations (with recent data) - Colchicine (microtubule inhibitor): attenuates NLRP3 activation and NETosis; first‑line anti‑inflammatory for flares, with expanding evidence in cardiometabolic disease linking its mechanisms to microtubule‑dependent inflammasome and NET regulation (supportive mechanistic context) (tan2024mechanismofmacrophages pages 2-4, herdiana2025currentstatusof pages 2-4). - IL‑1 pathway blockade: Canakinumab (anti–IL‑1β) and anakinra (IL‑1 receptor antagonist) reduce pain and flare frequency in RCTs/real‑world settings; used for patients who cannot tolerate NSAIDs/colchicine or have refractory disease. (sanchez2024effectivexanthineoxidase pages 8-9) - XO inhibitors (allopurinol, febuxostat): titrate‑to‑target serum urate <6 mg/dL (often <5 mg/dL in tophaceous gout). At ~48 weeks, responders show reduced flares with a coordinated shift in serum/immune proteomics featuring complement and inflammatory nodes, consistent with pathway remodeling as crystal burden regresses (Scientific Reports, Oct 2024; https://doi.org/10.1038/s41598-024-74154-5). (sanchez2024effectivexanthineoxidase pages 9-10, sanchez2024effectivexanthineoxidase pages 8-9) - SGLT2 inhibitors (diabetes and gout comorbidity): robust, recent evidence demonstrates fewer gout outcomes— • Among patients with gout and T2D, SGLT2i vs DPP‑4i: 52.4 vs 79.7 recurrent flares per 1000 person‑years; RR 0.66 (95% CI 0.57–0.75); RD −27.4 (−36.0 to −18.7) per 1000 person‑years. Gout‑primary ED/hospitalizations RR 0.52 (0.32–0.84). Myocardial infarction HR 0.69 (0.54–0.88). Ann Intern Med; Aug 2023; https://doi.org/10.7326/m23-0724. (mccormick2023comparativeeffectivenessof pages 1-3, mccormick2023comparativeeffectivenessof pages 5-6) • Incident gout (empagliflozin vs DPP‑4i): HR 0.69 (95% CI 0.60–0.79); vs GLP‑1RA: HR 0.83 (0.73–0.94); J Gen Intern Med; May 2024; https://doi.org/10.1007/s11606-024-08793-9. (tesfaye2024empagliflozinandrisk pages 1-2) • Target‑trial emulation in nephrolithiasis cohorts also found lower gout flare rates: RR 0.72 (0.54–0.95) vs GLP‑1RA; RR 0.65 (0.52–0.82) vs DPP‑4i (BMJ; Oct 2024; https://doi.org/10.1136/bmj-2024-080035). (mccormick2024comparativeeffectivenessof pages 1-2)
Expert Opinions and Authoritative Analyses - Systems and macrophage‑centric views emphasize NLRP3’s centrality and multiple regulatory nodes (complement C5a axis, metabolic reprogramming, ROS) as translational targets in gout (Heliyon; 2024). (tan2024mechanismofmacrophages pages 11-12) - Proteomics integrated with clinical ULT responses support complement/inflammation pathway remodeling as a correlate of effective crystal burden reduction and flare decline (Scientific Reports; 2024). (sanchez2024effectivexanthineoxidase pages 8-9)
Relevant Statistics and Data (recent) - SGLT2i reduce recurrent flare rates by ~34% and gout‑primary ED/hospitalizations by ~48% vs DPP‑4i among gout patients with T2D (Ann Intern Med 2023; DOI above). (mccormick2023comparativeeffectivenessof pages 1-3, mccormick2023comparativeeffectivenessof pages 5-6) - Empagliflozin lowers incident gout risk vs DPP‑4i (HR 0.69) and GLP‑1RA (HR 0.83) over ~8 months (J Gen Intern Med 2024; DOI above). (tesfaye2024empagliflozinandrisk pages 1-2) - XO inhibitor ULT at ~48 weeks associates with an emergent serum interactome enriched in complement and inflammatory modules in responders (Scientific Reports 2024; DOI above). (sanchez2024effectivexanthineoxidase pages 9-10, sanchez2024effectivexanthineoxidase pages 8-9)
Gene/Protein Annotations, Ontology Terms, Cell Types, Anatomy, Chemicals, and Evidence Table | Category | Entity (preferred name) | Ontology (HGNC/GO/CL/UBERON/CHEBI) | Identifier | Role / Notes | Key Evidence | |---|---|---:|---|---|---| | Gene / Transporter | SLC2A9 (GLUT9) | HGNC | SLC2A9 | Major renal/intestinal urate reuptake/exporter; strong genetic determinant of serum urate | (lin2024thetherapeuticmanagement pages 2-5, sanchez2024effectivexanthineoxidase pages 9-10) | | Gene / Transporter | ABCG2 (BCRP) | HGNC | ABCG2 | Intestinal/renal urate exporter; loss-of-function variants increase hyperuricemia/gout risk | (lin2024thetherapeuticmanagement pages 2-5, sanchez2024effectivexanthineoxidase pages 9-10) | | Gene / Transporter | SLC22A12 (URAT1) | HGNC | SLC22A12 | Renal urate reuptake transporter; target of uricosuric drugs | (lin2024thetherapeuticmanagement pages 2-5, lin2024thetherapeuticmanagement pages 5-6) | | Gene / Transporter | SLC22A11 (OAT4) | HGNC | SLC22A11 | Renal organic anion transporter implicated in urate handling | (lin2024thetherapeuticmanagement pages 2-5) | | Gene / Transporter | SLC17A1 (NPT1) | HGNC | SLC17A1 | Renal urate secretion candidate (phosphate/anion transporter family) | (lin2024thetherapeuticmanagement pages 2-5) | | Gene / Transporter | MOCOS | HGNC | MOCOS | Involved in allopurinol metabolism (oxypurinol pathway); variants associate with poor allopurinol response | (sanchez2024effectivexanthineoxidase pages 9-10) | | Inflammasome component | NLRP3 | HGNC / GO | NLRP3 / GO:inflammasome activation | Sensor for MSU crystals; central to caspase-1 activation and IL-1β/IL-18 maturation | (tan2024mechanismofmacrophages pages 2-4, tan2024mechanismofmacrophages pages 11-12) | | Inflammasome component | CASP1 (caspase-1) | HGNC | CASP1 | Executes pro-IL-1β/IL-18 cleavage; links inflammasome assembly to cytokine release | (tan2024mechanismofmacrophages pages 2-4, tan2024mechanismofmacrophages pages 11-12) | | Cytokine | IL1B (IL-1β) | HGNC | IL1B | Principal pro-inflammatory mediator driving neutrophil recruitment / gout flare symptoms | (tan2024mechanismofmacrophages pages 2-4, sanchez2024effectivexanthineoxidase pages 9-10) | | Cytokine | IL18 (IL-18) | HGNC | IL18 | Inflammasome product elevated in hyperuricaemia/gout; contributes to inflammation | (tan2024mechanismofmacrophages pages 11-12, chen2024mechanismofneutrophil pages 8-8) | | Effector / Pyroptosis | GSDMD (gasdermin D) | HGNC | GSDMD | Forms membrane pores in pyroptosis downstream of caspase-1/4/11; implicated in MSU-induced cell death | (tan2024mechanismofmacrophages pages 2-4, chen2024mechanismofneutrophil pages 8-8) | | Cell type | Macrophage | CL | macrophage (synovial/tissue macrophage) | Phagocytose MSU crystals, assemble NLRP3 inflammasome, source of IL-1β and pyroptotic responses | (tan2024mechanismofmacrophages pages 2-4, tan2024mechanismofmacrophages pages 11-12) | | Cell type | Neutrophil | CL | neutrophil | Recruited by IL-1β/CXCL8; form NETs/aggNETs that amplify acute inflammation but can aggregate to resolve inflammation | (chen2024mechanismofneutrophil pages 8-8, herdiana2025currentstatusof pages 2-4) | | Cell type | Mast cell | CL | mast cell | Contribute to early inflammatory mediator release in crystal arthritis (histamine, cytokines) | (lin2024thetherapeuticmanagement pages 2-5, sanchez2024effectivexanthineoxidase pages 9-10) | | Process / GO | NETosis (neutrophil extracellular traps) | GO | NETosis / GO: (NET formation) | NETs trap/degrade cytokines (aggNETs aid resolution) but also promote inflammation/osteoclastogenesis in chronic disease | (chen2024mechanismofneutrophil pages 8-8, herdiana2025currentstatusof pages 2-4) | | Process / GO | Pyroptosis | GO | Pyroptosis / GO: (inflammatory programmed cell death) | Caspase-1–GSDMD pathway in macrophages/neutrophils amplifies MSU-driven inflammation | (tan2024mechanismofmacrophages pages 2-4, chen2024mechanismofneutrophil pages 8-8) | | Process / GO | Autophagy | GO | Autophagy | Regulates NET formation and neutrophil responses; links to inflammation resolution mechanisms | (herdiana2025currentstatusof pages 2-4, chen2024mechanismofneutrophil pages 8-8) | | Process / GO | Complement activation | GO | Complement activation | MSU crystals activate complement (C5/C5a, MAC) augmenting neutrophil recruitment and inflammasome priming | (sanchez2024effectivexanthineoxidase pages 9-10) | | Process / Other | MSU biomineralization (crystal formation) | (biomineralization) | Monosodium urate crystallization | Cartilage matrix / damaged collagen templates and amorphous precursors nucleate biogenic MSU crystals over time | (sanchez2024effectivexanthineoxidase pages 8-9, chen2024mechanismofneutrophil pages 8-8) | | Anatomical site (UBERON) | Synovium | UBERON | Synovium | Primary site of MSU deposition and neutrophil-rich synovitis during flares | (herdiana2025currentstatusof pages 2-4, sanchez2024effectivexanthineoxidase pages 9-10) | | Anatomical site (UBERON) | Cartilage | UBERON | Cartilage | Cartilage damage provides nucleation surfaces (collagen fibrils) for AMSU → MSU crystal formation | (sanchez2024effectivexanthineoxidase pages 8-9) | | Anatomical site (UBERON) | Bone | UBERON | Bone | Tophi-associated chronic inflammation and RANKL-driven osteoclast activation cause erosions | (herdiana2025currentstatusof pages 2-4, chen2024mechanismofneutrophil pages 8-8) | | Anatomical site (UBERON) | Kidney | UBERON | Kidney | Key organ for urate excretion; reduced renal excretion major cause of hyperuricemia and nephrolithiasis risk | (lin2024thetherapeuticmanagement pages 2-5, sanchez2024effectivexanthineoxidase pages 9-10) | | Anatomical site (UBERON) | Intestine | UBERON | Intestine | Alternative urate excretion route (ABCG2 role); gut microbiota influence urate metabolism | (lin2024thetherapeuticmanagement pages 2-5) | | Chemical / CHEBI | Uric acid (urate) | CHEBI | Uric acid / urate | Final human purine catabolite; supersaturation drives MSU crystallization; modulated by XO activity and transporters | (lin2024thetherapeuticmanagement pages 2-5, sanchez2024effectivexanthineoxidase pages 9-10) | | Chemical / CHEBI | Monosodium urate (MSU) | CHEBI | MSU crystal | Crystalline trigger for inflammasome activation, complement activation, NETosis, and local tissue injury | (sanchez2024effectivexanthineoxidase pages 8-9, chen2024mechanismofneutrophil pages 8-8) | | Drug / CHEBI | Allopurinol (XOI) | CHEBI | Allopurinol | Xanthine oxidase inhibitor; lowers urate production; genetic variation (MOCOS, ABCG2) modulates response | (sanchez2024effectivexanthineoxidase pages 9-10) | | Drug / CHEBI | Febuxostat (XOI) | CHEBI | Febuxostat | Non-purine XOI; effective ULT linked to remodeling of complement/inflammatory serum proteome | (sanchez2024effectivexanthineoxidase pages 9-10) | | Drug / CHEBI | Canakinumab (anti–IL-1β) | CHEBI | Canakinumab | Neutralizes IL-1β; effective in selected acute/refractory gout flares (IL-1 pathway blockade) | (sanchez2024effectivexanthineoxidase pages 9-10) | | Drug / CHEBI | Anakinra (IL-1 receptor antagonist) | CHEBI | Anakinra | Blocks IL-1 signaling; used off-label / in difficult-to-treat acute flares with good efficacy/safety data | (sanchez2024effectivexanthineoxidase pages 9-10) | | Drug / CHEBI | Colchicine | CHEBI | Colchicine | Inhibits microtubule dynamics → reduces NLRP3 activation and NETosis; first-line anti-inflammatory for flares | (tan2024mechanismofmacrophages pages 2-4, herdiana2025currentstatusof pages 2-4) | | Drug class | SGLT2 inhibitors | CHEBI / drug class | SGLT2i | Reduce serum urate and are associated with lower gout incidence/flares in diabetic cohorts (class effect evidence) | (sanchez2024effectivexanthineoxidase pages 9-10) |
Table: Concise ontology-linked mapping of key genes, proteins, cells, processes, anatomical sites and drugs in gout pathophysiology, with primary evidence citations to the gathered sources; useful for knowledge-base annotation and GO/CL/UBERON/CHEBI mapping.
Selected Evidence Items with URLs and dates - Rodriguez‑Navarro C, et al. Unraveling the pathological biomineralization of monosodium urate crystals in gout patients. Communications Biology. July 2024. https://doi.org/10.1038/s42003-024-06534-6 (MSU crystallization via amorphous precursor on collagen). (sanchez2024effectivexanthineoxidase pages 8-9) - Tan H, et al. Mechanism of macrophages in gout: Recent progress and perspective. Heliyon. Oct 2024. https://doi.org/10.1016/j.heliyon.2024.e38288 (macrophage NLRP3 regulation). (tan2024mechanismofmacrophages pages 11-12) - Huang S, et al. Neutrophil autophagy… facilitates NETs and inflammation remission in gouty arthritis. Frontiers in Endocrinology. Sept 2023. https://doi.org/10.3389/fendo.2023.1071630 (autophagy–NETs–remission). (herdiana2025currentstatusof pages 2-4) - Chen T, et al. Mechanism of NETs in gout. Clinical and Experimental Rheumatology. Jan 2024. https://doi.org/10.55563/clinexprheumatol/ezzfbt (NETs/aggNETs roles). (chen2024mechanismofneutrophil pages 8-8) - Sanchez C, et al. XO inhibitor ULT and emergent serum interactome. Scientific Reports. Oct 2024. https://doi.org/10.1038/s41598-024-74154-5 (complement/inflammation remodeling with ULT). (sanchez2024effectivexanthineoxidase pages 9-10, sanchez2024effectivexanthineoxidase pages 8-9) - Takada T, et al. Regulation of Urate Homeostasis by Membrane Transporters. Gout, Urate, and Crystal Deposition Disease. June 2024. https://doi.org/10.3390/gucdd2020016 (SLC2A9, ABCG2 roles). (lin2024thetherapeuticmanagement pages 2-5) - Fanning NC, et al. MOCOS and inadequate allopurinol response. Rheumatology (Oxford). Aug 2024. https://doi.org/10.1093/rheumatology/keae420. (sanchez2024effectivexanthineoxidase pages 9-10) - McCormick N, et al. SGLT2i vs DPP‑4i for recurrent gout flares. Ann Intern Med. Aug 2023. https://doi.org/10.7326/m23-0724. (mccormick2023comparativeeffectivenessof pages 1-3, mccormick2023comparativeeffectivenessof pages 5-6) - Tesfaye H, et al. Empagliflozin and incident gout. J Gen Intern Med. May 2024. https://doi.org/10.1007/s11606-024-08793-9. (tesfaye2024empagliflozinandrisk pages 1-2) - McCormick N, et al. SGLT2i and nephrolithiasis/gout outcomes. BMJ. Oct 2024. https://doi.org/10.1136/bmj-2024-080035. (mccormick2024comparativeeffectivenessof pages 1-2)
Notes on Causality and Open Questions - Not all individuals with hyperuricemia develop gout, reflecting thresholds for in situ crystallization and immune activation, as well as host genetic and tissue‑matrix factors (e.g., collagen‑templated AMSU → MSU). (sanchez2024effectivexanthineoxidase pages 8-9) - Inflammasome activation can be modulated by complement and metabolic inputs; the precise conditions favoring pro‑ vs anti‑inflammatory NET programs (NETs vs aggNETs) remain active areas. (tan2024mechanismofmacrophages pages 11-12, herdiana2025currentstatusof pages 2-4)
References (indicative; see above entries for URLs) - Communications Biology 2024 (MSU crystal biomineralization) (sanchez2024effectivexanthineoxidase pages 8-9) - Heliyon 2024 (macrophage NLRP3 regulation) (tan2024mechanismofmacrophages pages 11-12) - Frontiers in Endocrinology 2023 (autophagy–NETs) (herdiana2025currentstatusof pages 2-4) - Clinical and Experimental Rheumatology 2024 (NETs) (chen2024mechanismofneutrophil pages 8-8) - Scientific Reports 2024 (ULT proteomics) (sanchez2024effectivexanthineoxidase pages 9-10, sanchez2024effectivexanthineoxidase pages 8-9) - Gout, Urate, and Crystal Deposition Disease 2024 (transporters) (lin2024thetherapeuticmanagement pages 2-5) - Rheumatology (Oxford) 2024 (MOCOS pharmacogenetics) (sanchez2024effectivexanthineoxidase pages 9-10) - Annals of Internal Medicine 2023; J Gen Intern Med 2024; BMJ 2024 (SGLT2 outcomes) (mccormick2023comparativeeffectivenessof pages 1-3, tesfaye2024empagliflozinandrisk pages 1-2, mccormick2024comparativeeffectivenessof pages 1-2)
References
(sanchez2024effectivexanthineoxidase pages 8-9): Concepcion Sanchez, Anaamika Campeau, Ru Liu-Bryan, Ted R. Mikuls, James R. O’Dell, David J. Gonzalez, and Robert Terkeltaub. Effective xanthine oxidase inhibitor urate lowering therapy in gout is linked to an emergent serum protein interactome of complement and inflammation modulators. Scientific Reports, Oct 2024. URL: https://doi.org/10.1038/s41598-024-74154-5, doi:10.1038/s41598-024-74154-5. This article has 7 citations and is from a peer-reviewed journal.
(herdiana2025currentstatusof pages 2-4): Yedi Herdiana, Yoga Windhu Wardhana, Insan Sunan Kurniawansyah, Dolih Gozali, Nasrul Wathoni, and Ferry Ferdiansyah Sofian. Current status of gout arthritis: current approaches to gout arthritis treatment: nanoparticles delivery systems approach. Pharmaceutics, 17:102, Jan 2025. URL: https://doi.org/10.3390/pharmaceutics17010102, doi:10.3390/pharmaceutics17010102. This article has 8 citations and is from a poor quality or predatory journal.
(tan2024mechanismofmacrophages pages 2-4): Haibo Tan, Shan Zhang, Junlan Liao, Xia Qiu, Zhihao Zhang, Ziyu Wang, Hongling Geng, Jianyong Zhang, and Ertao Jia. Mechanism of macrophages in gout: recent progress and perspective. Heliyon, 10:e38288, Oct 2024. URL: https://doi.org/10.1016/j.heliyon.2024.e38288, doi:10.1016/j.heliyon.2024.e38288. This article has 9 citations and is from a peer-reviewed journal.
(tan2024mechanismofmacrophages pages 11-12): Haibo Tan, Shan Zhang, Junlan Liao, Xia Qiu, Zhihao Zhang, Ziyu Wang, Hongling Geng, Jianyong Zhang, and Ertao Jia. Mechanism of macrophages in gout: recent progress and perspective. Heliyon, 10:e38288, Oct 2024. URL: https://doi.org/10.1016/j.heliyon.2024.e38288, doi:10.1016/j.heliyon.2024.e38288. This article has 9 citations and is from a peer-reviewed journal.
(sanchez2024effectivexanthineoxidase pages 9-10): Concepcion Sanchez, Anaamika Campeau, Ru Liu-Bryan, Ted R. Mikuls, James R. O’Dell, David J. Gonzalez, and Robert Terkeltaub. Effective xanthine oxidase inhibitor urate lowering therapy in gout is linked to an emergent serum protein interactome of complement and inflammation modulators. Scientific Reports, Oct 2024. URL: https://doi.org/10.1038/s41598-024-74154-5, doi:10.1038/s41598-024-74154-5. This article has 7 citations and is from a peer-reviewed journal.
(lin2024thetherapeuticmanagement pages 5-6): Zhijian Lin, Jeetendra Kumar Gupta, Mohsin Maqbool, Krishan Kumar, Ayushi Sharma, and Nitin Wahi. The therapeutic management of chemical and herbal medications on uric acid levels and gout: modern and traditional wisdom. Pharmaceuticals, 17:1507, Nov 2024. URL: https://doi.org/10.3390/ph17111507, doi:10.3390/ph17111507. This article has 7 citations and is from a poor quality or predatory journal.
(lin2024thetherapeuticmanagement pages 2-5): Zhijian Lin, Jeetendra Kumar Gupta, Mohsin Maqbool, Krishan Kumar, Ayushi Sharma, and Nitin Wahi. The therapeutic management of chemical and herbal medications on uric acid levels and gout: modern and traditional wisdom. Pharmaceuticals, 17:1507, Nov 2024. URL: https://doi.org/10.3390/ph17111507, doi:10.3390/ph17111507. This article has 7 citations and is from a poor quality or predatory journal.
(chen2024mechanismofneutrophil pages 8-8): Tingting Chen, Jingguo Zhou, and Wantai Dang. Mechanism of neutrophil extracellular traps in the pathogenesis of gout. Clinical and experimental rheumatology, Jan 2024. URL: https://doi.org/10.55563/clinexprheumatol/ezzfbt, doi:10.55563/clinexprheumatol/ezzfbt. This article has 6 citations and is from a peer-reviewed journal.
(mccormick2023comparativeeffectivenessof pages 1-3): PhD Natalie McCormick, MD MSc Chio Yokose, PhD Jie Wei, Mph Na Lu, MD MSc Deborah J. Wexler, MD PhD J. Antonio Aviña-Zubieta, PhD Mary A. De Vera, ScD Yuqing Zhang, and M. D. Hyon K. Choi. Comparative effectiveness of sodium–glucose cotransporter-2 inhibitors for recurrent gout flares and gout-primary emergency department visits and hospitalizations. Annals of Internal Medicine, 176:1067-1080, Aug 2023. URL: https://doi.org/10.7326/m23-0724, doi:10.7326/m23-0724. This article has 37 citations and is from a highest quality peer-reviewed journal.
(mccormick2023comparativeeffectivenessof pages 5-6): PhD Natalie McCormick, MD MSc Chio Yokose, PhD Jie Wei, Mph Na Lu, MD MSc Deborah J. Wexler, MD PhD J. Antonio Aviña-Zubieta, PhD Mary A. De Vera, ScD Yuqing Zhang, and M. D. Hyon K. Choi. Comparative effectiveness of sodium–glucose cotransporter-2 inhibitors for recurrent gout flares and gout-primary emergency department visits and hospitalizations. Annals of Internal Medicine, 176:1067-1080, Aug 2023. URL: https://doi.org/10.7326/m23-0724, doi:10.7326/m23-0724. This article has 37 citations and is from a highest quality peer-reviewed journal.
(tesfaye2024empagliflozinandrisk pages 1-2): Helen Tesfaye, Katherine M. Wang, Luke E. Zabotka, Deborah J. Wexler, Niklas Schmedt, Lisette Koeneman, Leo Seman, Julie M. Paik, and Elisabetta Patorno. Empagliflozin and risk of incident gout: analysis from the empagliflozin comparative effectiveness and safety (emprise) cohort study. Journal of general internal medicine, 39:1870-1879, May 2024. URL: https://doi.org/10.1007/s11606-024-08793-9, doi:10.1007/s11606-024-08793-9. This article has 6 citations and is from a peer-reviewed journal.
(mccormick2024comparativeeffectivenessof pages 1-2): Natalie McCormick, Chio Yokose, Na Lu, Deborah J Wexler, J Antonio Aviña-Zubieta, Mary A De Vera, Saiajay Chigurupati, Kiara Tan, Chixiang Chen, Rozalina McCoy, Gary C Curhan, and Hyon K Choi. Comparative effectiveness of sodium-glucose cotransporter-2 inhibitors for recurrent nephrolithiasis among patients with pre-existing nephrolithiasis or gout: target trial emulation studies. BMJ, 387:e080035, Oct 2024. URL: https://doi.org/10.1136/bmj-2024-080035, doi:10.1136/bmj-2024-080035. This article has 17 citations and is from a domain leading peer-reviewed journal.